Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,000

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Intra-tumour heterogeneity: a looking glass for cancer?

Marusyk, Andriy, Almendro, Vanessa, Polyak, Kornelia·2012·Nature Reviews Cancer
DOI 10.1038/nrc3261
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3261

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 93

  1. Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38, 2651–2660 (1978).
  2. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011). This paper demonstrated substantial genetic variability in putative driver mutations between leukaemia stem cells, suggesting complex patterns of clonal evolution. · DOI · Paper page
  3. Campbell, L. L. & Polyak, K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6, 2332–2338 (2007). · DOI · Paper page
  4. Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822–829 (2009). · DOI · Paper page
  5. Notta, F. et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469, 362–367 (2011). This paper demonstrated substantial genetic diversity between leukaemia-initiating cells, suggesting complex clonal architecture. · DOI · Paper page
  6. Shipitsin, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259–273 (2007). This paper demonstrated that presumed stem cell and non-stem cell subpopulations in breast tumours can have different patterns of mutations. · DOI · Paper page
  7. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789–799 (2004). · DOI · Paper page
  8. Rangarajan, A., Hong, S. J., Gifford, A. & Weinberg, R. A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6, 171–183 (2004). · DOI · Paper page
  9. Ruiz, C. et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc. Natl Acad. Sci. USA 108, 12054–12059 (2011). · DOI
  10. Ashworth, A., Lord, C. J. & Reis-Filho, J. S. Genetic interactions in cancer progression and treatment. Cell 145, 30–38 (2011). · DOI · Paper page
  11. Raj, A. & van Oudenaarden, A. Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 135, 216–226 (2008). · DOI · Paper page
  12. Niepel, M., Spencer, S. L. & Sorger, P. K. Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr. Opin. Chem. Biol. 13, 556–561 (2009). · DOI · Paper page
  13. Altschuler, S. J. & Wu, L. F. Cellular heterogeneity: do differences make a difference? Cell 141, 559–563 (2010). · DOI · Paper page
  14. Huang, S. Non-genetic heterogeneity of cells in development: more than just noise. Development 136, 3853–3862 (2009). · DOI · Paper page
  15. Eldar, A. & Elowitz, M. B. Functional roles for noise in genetic circuits. Nature 467, 167–173 (2010). · DOI · Paper page
  16. Dalerba, P. et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nature Biotechnol. 29, 1120–1127 (2011). · DOI · Paper page
  17. Clevers, H. The cancer stem cell: premises, promises and challenges. Nature Med. 17, 313–319 (2011). · DOI · Paper page
  18. Rosen, J. M. & Jordan, C. T. The increasing complexity of the cancer stem cell paradigm. Science 324, 1670–1673 (2009). · DOI · Paper page
  19. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA. 108, 7950–7955 (2011). · DOI · Paper page
  20. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008). · DOI · Paper page
  21. Balazsi, G., van Oudenaarden, A. & Collins, J. J. Cellular decision making and biological noise: from microbes to mammals. Cell 144, 910–925 (2011). · DOI · Paper page
  22. Arias, A. M. & Hayward, P. Filtering transcriptional noise during development: concepts and mechanisms. Nature Rev. Genet. 7, 34–44 (2006). · DOI · Paper page
  23. Hughes, T. R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109–126 (2000). · DOI · Paper page
  24. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009). · DOI · Paper page
  25. Egeblad, M., Nakasone, E. S. & Werb, Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18, 884–901 (2010). · DOI · Paper page
  26. Tlsty, T. D. & Coussens, L. M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119–150 (2006). · DOI · Paper page
  27. Bissell, M. J., Kenny, P. A. & Radisky, D. C. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb. Symp. Quant. Biol. 70, 343–356 (2005). · DOI · Paper page
  28. Anderson, A. R., Weaver, A. M., Cummings, P. T. & Quaranta, V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127, 905–915 (2006). · DOI · Paper page
  29. Chen, J., Sprouffske, K., Huang, Q. & Maley, C. C. Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PloS ONE 6, e17933 (2011). · DOI
  30. Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev. Cancer 3, 411–421 (2003). · DOI · Paper page
  31. Radisky, D. C. & Bissell, M. J. Matrix metalloproteinase-induced genomic instability. Curr. Opin. Genet. Dev. 16, 45–50 (2006). · DOI
  32. Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071–1121 (2011). · DOI · Paper page
  33. Farmer, P. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Med. 15, 68–74 (2009). · DOI · Paper page
  34. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature Med. 14, 518–527 (2008). · DOI · Paper page
  35. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nature Rev. Cancer 6, 924–935 (2006). · DOI · Paper page
  36. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683–692 (2007). · DOI · Paper page
  37. Brock, A., Chang, H. & Huang, S. Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours. Nature Rev. Genetics 10, 336–342 (2009). · DOI · Paper page
  38. Weinberg, R. A. The Biology of Cancer (Garland Science, 2007).
  39. Barrick, J. E. & Lenski, R. E. Genome-wide mutational diversity in an evolving population of Escherichia coli. Cold Spring Harb. Symp. Quant. Biol. 74, 119–129 (2009). · DOI · Paper page
  40. Desai, M. M., Fisher, D. S. & Murray, A. W. The speed of evolution and maintenance of variation in asexual populations. Curr. Biol. 17, 385–394 (2007). · DOI · Paper page
  41. Marusyk, A. & Polyak, K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105–117 (2010).
  42. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94 (2011). The first report that interrogated genomic-wide diversity within tumours on a single-cell level. · DOI · Paper page
  43. Tsao, J. L. et al. Colorectal adenoma and cancer divergence. Evidence of multilineage progression. Am. J. Pathol. 154, 1815–1824 (1999).
  44. Gonzalez-Garcia, I., Sole, R. V. & Costa, J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc. Natl Acad. Sci. USA 99, 13085–13089 (2002). · DOI · Paper page
  45. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810–817 (2011). · DOI · Paper page
  46. Stoecklein, N. H. & Klein, C. A. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer. 126, 589–598 (2010). · DOI
  47. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990). · DOI · Paper page
  48. Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49–54 (2003). · DOI · Paper page
  49. Weigelt, B. et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65, 9155–9158 (2005). · DOI · Paper page
  50. Klein, C. A. Parallel progression of primary tumours and metastases. Nature Rev. Cancer 9, 302–312 (2009). · DOI · Paper page
  51. Mardis, E. R. Cancer genomics identifies determinants of tumor biology. Genome Biol. 11, 211 (2010). · DOI
  52. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813 (2009). The first report that used next-generation sequencing to interrogate clonal diversity and evolution during breast cancer progression. · DOI · Paper page
  53. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010). · DOI · Paper page
  54. Perou, C. M., Parker, J. S., Prat, A., Ellis, M. J. & Bernard, P. S. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 11, 718–719 (2010). · DOI
  55. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001). · DOI · Paper page
  56. Komaki, K., Sano, N. & Tangoku, A. Problems in histological grading of malignancy and its clinical significance in patients with operable breast cancer. Breast cancer 13, 249–253 (2006). · DOI
  57. Bertos, N. R. & Park, M. Breast cancer - one term, many entities? J. Clin. Invest. 121, 3789–3796 (2011). · DOI · Paper page
  58. Allred, D. C. et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 14, 370–378 (2008). · DOI · Paper page
  59. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genet. 38, 468–473 (2006). This paper linked higher extent of genetic clonal diversity with poor clinical outcome. · DOI · Paper page
  60. Merlo, L. M. & Maley, C. C. The role of genetic diversity in cancer. J. Clin. Invest. 120, 401–403 (2010). · DOI
  61. Park, S. Y. et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 16, 876–887 (2010). · DOI · Paper page
  62. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009). · DOI · Paper page
  63. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009). · DOI · Paper page
  64. Deininger, M. Resistance to imatinib: mechanisms and management. J. Natl Compr. Canc. Netw. 3, 757–768 (2005). · DOI
  65. Corless, C. L. & Heinrich, M. C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol. 3, 557–586 (2008). · DOI · Paper page
  66. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010). · DOI · Paper page
  67. Roche-Lestienne, C., Lai, J. L., Darre, S., Facon, T. & Preudhomme, C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N. Engl. J. Med. 348, 2265–2266 (2003). · DOI
  68. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380 (2008). · DOI · Paper page
  69. Janne, P. A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Rev. Drug Discov. 8, 709–723 (2009). · DOI · Paper page
  70. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010). This study linked therapy resistance with a distinct epigenetic switch that arises through a spontaneous phenotypic switch. Although this phenotypic state is reversible, it can persist for multiple cell generations and thus serve as a substrate for Darwinian selection. · DOI · Paper page
  71. Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511–1516 (2008). · DOI · Paper page
  72. Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M. & Sorger, P. K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459, 428–432 (2009). This study implicated noise-driven stochastic non-genetic variability in short-term resistance to therapy. · DOI · Paper page
  73. Heppner, G. H. Cancer cell societies and tumor progression. Stem Cells 11, 199–203 (1993). · doi:10.1002/stem.5530110306
  74. Bonavia, R., Inda, M. M., Cavenee, W. K. & Furnari, F. B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71, 4055–4060 (2011). · DOI · Paper page
  75. Park, S. Y., Gönen, M., Kim, H. J., Michor, F. & Polyak, K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J. Clin. Invest. 120, 636–644 (2010). · DOI · Paper page
  76. Merlo, L. M. et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila) 3, 1388–1397 (2010). · DOI
  77. Russnes, H. G., Navin, N., Hicks, J. & Borresen-Dale, A. L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 121, 3810–3818 (2011). · DOI · Paper page
  78. Navin, N. et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 20, 68–80 (2010). · DOI · Paper page
  79. Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886–895 (2012). · DOI · Paper page
  80. Hou, Y. et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873–885 (2012). · DOI · Paper page
  81. Miller, B. E., Machemer, T., Lehotan, M. & Heppner, G. H. Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors. Cancer Res. 51, 4378–4387 (1991).
  82. Calbo, J. et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19, 244–256 (2011). · DOI · Paper page
  83. Marks, P. A. & Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497–1511 (2005). · DOI · Paper page
  84. Gregory, R. I. & Shiekhattar, R. Chromatin modifiers and carcinogenesis. Trends Cell. Biol. 14, 695–702 (2004). · DOI
  85. Bissell, M. J. & Hines, W. C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Med. 17, 320–329 (2011). · DOI · Paper page
  86. Attolini, C. S. & Michor, F. Evolutionary theory of cancer. Ann. NY Acad. Sci. 1168, 23–51 (2009). · DOI
  87. DeGregori, J. Evolved tumor suppression: why are we so good at not getting cancer? Cancer Res. 71, 3739–3744 (2011). · DOI
  88. Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894–4903 (2009). This paper proposes 'adaptive therapy', which takes into account clonal competition in order to prevent therapy-resistant cells from taking over the population. · DOI · Paper page
  89. Waddington, C. H. The Strategy of the Genes: a Discussion of Some Aspects of Theoretical Biology (Taylor & Francis, 1957).
  90. Huang, S. & Kauffman, S. A. in Encyclopedia of Complexity and Systems Science (ed. Meyers, R. A.) 1180–1213 (Springer, 2009). · DOI
  91. Fisher, A. G. Cellular identity and lineage choice. Nature Rev. Immunol. 2, 977–982 (2002). · DOI
  92. Bozic, I. et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl Acad. Sci. USA 107, 18545–18550 (2010). · DOI · Paper page
  93. Leedham, S. J. et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 57, 1041–1948 (2008). · DOI · Paper page

Cited by

See all 2,000

Metadata

Authors
Marusyk, A., Almendro, V., & Polyak, K.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2012-04-19
Volume
12
Issue
5
Pages
323-334
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc3261
OpenAlex
W1987012261
Cited by
2,000
References
14
FWCI
7.73
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intra-tumour heterogeneity: a looking glass for cancer? https://app.cochat.ai/papers/10.1038/nrc3261
The paper
Marusyk, A., Almendro, V., & Polyak, K. (2012). Intra-tumour heterogeneity: a looking glass for cancer? Nature Reviews Cancer. https://doi.org/10.1038/nrc3261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.